By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eisai Inc. 

900 Davis Drive
P.O. Box 14505
Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-941-6920 Fax: 919-941-6931

Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit

Key Statistics

Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: 2600
Symbol: ESALF.PK


Company News
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Announce BELVIQ® (lorcaserin HCl) CIV Nominated A Second Time For The Prix Galien Award In The Best Pharmaceutical Agent Category 7/29/2014 8:04:43 AM
Eisai Inc. (ESALF.PK) & Helsinn Group To Present New CINV Research At 2014 International Symposium On Supportive Care In Cancer 6/26/2014 6:59:08 AM
Barry Lederman Appointed Vice President And Chief Financial Officer Of Eisai Inc. (ESALF.PK) 6/23/2014 8:11:48 AM
Eisai Inc. (ESALF.PK)'s Antiepileptic Drug Perampanel Meets Primary Endpoint In Phase 3 Study 6/17/2014 6:15:31 AM
Eisai Inc. (ESALF.PK) Sponsors The Epilepsy Foundation Of Metropolitan New York's 2nd Annual Epilepsy Awareness Day At Citi Field 6/13/2014 7:11:58 AM
Eisai Inc. (ESALF.PK)'s New Thyroid Cancer Drug Lenvatinib Shows Promise In Phase 3 Study 6/2/2014 6:41:45 AM
Eisai Inc. (ESALF.PK) Launches National Television Advertising Campaign For BELVIQ® (lorcaserin HCl) CIV 4/14/2014 8:05:37 AM
Otsuka Pharmaceutical Co., Ltd. Acquires Rights To Hematological Cancer Treatment Dacogen® From Eisai Inc. (ESALF.PK) (U.S.) 3/31/2014 8:21:36 AM
Eisai Inc. (ESALF.PK)'s President And CEO To Retire 3/10/2014 7:34:24 AM
Eisai Inc. (ESALF.PK) Announces Initiation Of A Phase 3 Trial Of Eribulin Mesylate Injection Versus Weekly Paclitaxel In First And Second Lines Of Metastatic Breast Cancer 2/27/2014 10:17:47 AM